ALEC Company Profile and Key Details
NASDAQ : ALEC
Alector
$1.96
0.14+7.69%
At Close 4:00 PM60.69
BESG ScoreESG Rating
Price Chart
Stock Price Today
Alector, Inc. (ALEC) stock surged +7.69%, trading at $1.96 on NASDAQ, up from the previous close of $1.82. The stock opened at $1.83, fluctuating between $1.83 and $1.96 in the recent session.
Stock Snapshot
1.82
Prev. Close
213.94M
Market Cap
1.83
Day Low
-1.85
P/E Ratio
-1.06
EPS (TTM)
-2.21
Cash Flow per Share
1.83
Open
109.15M
Number of Shares
1.96
Day High
83.56%
Free Float in %
1.59
Book Value
1.12M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 06, 2026 | 1.83 | 1.96 | 1.83 | 1.96 | 1.12M |
| Feb 05, 2026 | 1.81 | 1.90 | 1.75 | 1.82 | 1.67M |
| Feb 04, 2026 | 1.96 | 1.98 | 1.87 | 1.93 | 721.61K |
| Feb 03, 2026 | 1.98 | 2.05 | 1.89 | 1.93 | 789.23K |
| Feb 02, 2026 | 1.87 | 2.03 | 1.84 | 1.99 | 846.73K |
| Jan 30, 2026 | 1.87 | 1.90 | 1.81 | 1.89 | 1.2M |
| Jan 29, 2026 | 1.93 | 1.93 | 1.90 | 1.91 | 466.34K |
| Jan 28, 2026 | 1.96 | 1.97 | 1.85 | 1.91 | 777.95K |
| Jan 27, 2026 | 1.95 | 1.98 | 1.91 | 1.95 | 226.78K |
| Jan 26, 2026 | 1.93 | 2.00 | 1.90 | 1.93 | 773.86K |
| Jan 23, 2026 | 1.89 | 1.94 | 1.88 | 1.94 | 665.45K |
| Jan 22, 2026 | 1.87 | 2.00 | 1.87 | 1.92 | 516.42K |
| Jan 21, 2026 | 1.82 | 1.93 | 1.81 | 1.92 | 688.99K |
| Jan 20, 2026 | 1.81 | 1.86 | 1.77 | 1.83 | 1.18M |
| Jan 16, 2026 | 1.80 | 1.98 | 1.78 | 1.84 | 1.21M |
| Jan 15, 2026 | 1.79 | 1.85 | 1.74 | 1.82 | 2.11M |
| Jan 14, 2026 | 1.92 | 1.93 | 1.84 | 1.85 | 1.29M |
| Jan 13, 2026 | 1.85 | 1.93 | 1.80 | 1.92 | 734.12K |
| Jan 12, 2026 | 1.84 | 1.85 | 1.71 | 1.84 | 1.27M |
| Jan 09, 2026 | 1.79 | 1.87 | 1.76 | 1.86 | 1.32M |
Contact Details
About Company
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Company Information
| Employees | 175 |
| Beta | 0.61 |
| Sales or Revenue | $97.06M |
| 5Y Sales Change% | 1.863% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
ARGX
-8.86-1.08%
argenx SE$811.45REGN18.88+2.46%
Regeneron Pharmaceuticals, Inc.$785.51UTHR6.43+1.34%
United Therapeutics Corporation$485.36VRTX19.11+4.17%
Vertex Pharmaceuticals Incorporated$477.92MDGL14.18+3.06%
Madrigal Pharmaceuticals, Inc.$477.60KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY-3.08-0.93%
Alnylam Pharmaceuticals, Inc.$328.16PRAX13.95+4.56%
Praxis Precision Medicines, Inc.$319.57KRYS5.1+1.91%
Krystal Biotech, Inc.$272.74SGEN-0.16-0.07%
Seagen Inc.$228.74Technical Performance
ALEC has shown mixed momentum, losing -0.54% over the past week and -39.8% over the past quarter, though year-to-date performance is up 17.31%. Short-term trend indicators are mixed aligned (SMA20 3.27%, SMA50 22.09%, SMA200 7.93%). The stock’s 14-day RSI is 60.83 (firm momentum), while the ATR of 0.12 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -42.35% below its high and over 125.29% above its low. Average 10-day trading volume of 868.99 thousand shares is below the 3-month average of 1.35 million, indicating normal recent market interest.
Dividend & Fair Value
Alector, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.02. This means the shares are trading below this model’s fair value.
Earnings & Analyst Outlook
Alector, Inc. generated EPS of -$1.07 over the past year. Five-year average earnings growth is 6.31%. Wall Street analysts project EPS growth of 1.36% annually over the next five years. The latest quarter delivered EPS of -$0.34. The next quarter is forecast at -$0.38. Next year's EPS is expected at -$19.15. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $7.00 to $1.50. The high target offers 257.14% upside. The low target suggests -23.47% downside. The mean target is $4.40. This offers 124.49% upside. Alector, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 06, 2025, missed forecasts by -19.05%. The prior quarter beat by -33.33%. Over the last six quarters, Apple has recorded several small beats. These include -18.37% in August 07, 2024.
Shareholding & Insider Activity
Alector, Inc. has 109.15 million shares outstanding. The public float is 78.19 million shares, elevated short interest at 7.36% of float. This equals 6.49 million shares. The short ratio is 5.55 days. Institutional investors hold 91.2% of the float. Insiders own 9.94%. MCGUIRE TERRANCE holds 10.85 million shares, Polaris Venture Management Co. VI, L.L.C. has 10.85 million shares and Rosenthal Arnon has 2.42 million shares. Over the past six months, insider transactions show net selling. They sold 307.06 thousand shares across 10 transactions.
Financial & Profitability Overview
On valuation metrics, Alector trades at a P/E of -1.86, P/S of 3.08 and P/B of 3.46. The current ratio is 3.76 and quick ratio is 3.76. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -37.37 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.66, supported by a cash flow-to-debt ratio of -5.21.
Quarterly Financial Highlights
The company ended the quarter with $548.86M in cash and short-term investments, a total debt of $38.92M, and net debt of - $35.64M. Total assets were $621.83M, with equity of $134.16M. Financials further reflected weakness, with operating cash flow of - $184.16M, free cash flow of - $186.54M, and capital expenditures of - $2.38M.
Frequently Asked Questions
What is the current Alector, Inc. (ALEC) stock price?
Alector, Inc. (NASDAQ: ALEC) stock price is $1.96 in the last trading session. During the trading session, ALEC stock reached the peak price of $1.96 while $1.83 was the lowest point it dropped to. The percentage change in ALEC stock occurred in the recent session was 7.69% while the dollar amount for the price change in ALEC stock was $0.14.
ALEC's industry and sector of operation?
The NASDAQ listed ALEC is part of Biotechnology industry that operates in the broader Healthcare sector. Alector, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of ALEC?
Mr. Calvin Yu
Vice President of Fin.
Dr. Tillman Ulf Gerngross Ph.D.
Co-Founder & Chairman
Mr. Peter Heutink Ph.D.
Chief Scientific Officer
Dr. Sara Kenkare-Mitra Ph.D.
Pres and Head of R&D
Ms. Danielle Pasqualone J.D., Ph.D.
Gen. Counsel
Ms. Kristina Cutter M.P.H.
Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
Erica Jefferson
Vice President of Communications & Public Affairs
Dr. Gary Romano M.D., Ph.D.
Chief Medical Officer
Michelle Corral
Vice President of Communications & Investor Relations
Dr. Marc Grasso M.D.
Advisor
Ms. Clare Hunt M.B.A.
Chief People Officer
Dr. Arnon Rosenthal Ph.D.
Founder
Vice President of Fin.
Dr. Tillman Ulf Gerngross Ph.D.
Co-Founder & Chairman
Mr. Peter Heutink Ph.D.
Chief Scientific Officer
Dr. Sara Kenkare-Mitra Ph.D.
Pres and Head of R&D
Ms. Danielle Pasqualone J.D., Ph.D.
Gen. Counsel
Ms. Kristina Cutter M.P.H.
Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer
Erica Jefferson
Vice President of Communications & Public Affairs
Dr. Gary Romano M.D., Ph.D.
Chief Medical Officer
Michelle Corral
Vice President of Communications & Investor Relations
Dr. Marc Grasso M.D.
Advisor
Ms. Clare Hunt M.B.A.
Chief People Officer
Dr. Arnon Rosenthal Ph.D.
Founder
How ALEC did perform over past 52-week?
ALEC's closing price is 125.29% higher than its 52-week low of $0.87 where as its distance from 52-week high of $3.40 is -42.35%.
How many employees does ALEC have?
Number of ALEC employees currently stands at 175.
Link for ALEC official website?
Official Website of ALEC is: https://www.alector.com
How do I contact ALEC?
ALEC could be contacted at phone 415 231 5660 and can also be accessed through its website. ALEC operates from 131 Oyster Point Boulevard, South San Francisco, CA 94080, United States.
How many shares of ALEC are traded daily?
ALEC stock volume for the day was 1.12M shares. The average number of ALEC shares traded daily for last 3 months was 1.34M.
What is the market cap of ALEC currently?
The market value of ALEC currently stands at $213.94M with its latest stock price at $1.96 and 109.15M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep